Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

NCT06996132 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Aggressive B-cell Lymphoma

Interventions

DRUG: Glofitamab
DRUG: Chimeric Antigen Receptor T Cells (CAR-T)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China